First Financial Bancorp and Capstar Financial Holdings are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlook of their businesses. I would suggest taking a look at my list of companies that compare favourably in all criteria, and consider whether they would add value to your current portfolio.
First Financial Bancorp. (NASDAQ:FFBC)
First Financial Bancorp. operates as the bank holding company for First Financial Bank that provides commercial banking and other banking, and banking-related services to individuals and businesses in Ohio, Indiana, and Kentucky. Established in 1863, and run by CEO Archie Brown, the company size now stands at 1,366 people and with the company’s market cap sitting at USD $2.83B, it falls under the mid-cap stocks category.
FFBC is expected to deliver a buoyant earnings growth over the next couple of years of 37.82%, bolstered by an equally impressive revenue growth of 81.81%. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 10.36%. FFBC’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add FFBC to your portfolio? I recommend researching its fundamentals here.
Capstar Financial Holdings, Inc. (NASDAQ:CSTR)
CapStar Financial Holdings, Inc. operates as the holding company for CapStar Bank that provides commercial banking services to consumer and corporate customers located primarily in Davidson, Sumner, Williamson, and the surrounding counties in Tennessee, the United States. Founded in 2007, and now run by Claire Tucker, the company employs 175 people and with the company’s market cap sitting at USD $217.38M, it falls under the small-cap category.
CSTR’s forecasted bottom line growth is an exceptional 69.54%, driven by the underlying 58.76% sales growth over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 9.79%. CSTR’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. A potential addition to your portfolio? I recommend researching its fundamentals here.
Akcea Therapeutics, Inc. (NASDAQ:AKCA)
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. Started in 2014, and headed by CEO Paula Soteropoulos, the company employs 100 people and has a market cap of USD $2.04B, putting it in the mid-cap stocks category.
AKCA is expected to deliver an extremely high earnings growth over the next couple of years of 51.75%, bolstered by a significant revenue which is expected to more than double. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. AKCA’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Want to know more about AKCA? Have a browse through its key fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.